Genedian

Genedian operates as a wholly-owned subsidiary of Dian Diagnostics (300244.SZ), one of China’s largest independent clinical laboratory (ICL) providers. The company focuses on pathology diagnostics and infection disease detection, developing digital pathology scanners, AI-assisted diagnosis software, and molecular diagnostic reagents for clinical and research applications.

Company Overview

Established as part of Dian Diagnostics’ vertical integration strategy, Genedian positions itself within the “pathology + infection” business framework while expanding into LDT (Laboratory Developed Test) precision medicine platforms. The company benefits from its parent’s extensive laboratory network spanning 37 facilities across China, serving over 22,000 medical institutions with 4,200+ diagnostic testing items.

Dian Diagnostics reported RMB 12.196 billion in revenue for 2024, with proprietary products contributing RMB 347 million. The group’s self-developed product portfolio now includes 2 Class III, 7 Class II, and 200 Class I medical device registrations obtained during 2024.

Core Products

Digital Pathology Slide Scanner Series

Genedian offers a complete range of whole-slide imaging (WSI) systems designed for clinical diagnosis, teleconsultation, and medical education:

DS600 - High-throughput scanner with 600-slide capacity for large pathology laboratories. NMPA registered (浙械注准20222220008) in 2022.

DS120 - Medium-throughput scanner with 120-slide capacity for routine pathology workflows.

DS12 - Compact scanner with 12-slide capacity for small laboratories and research applications.

All scanners feature multilayer fusion imaging technology supporting up to 15 focal planes, automated one-click scanning operation, and multiple output file formats for case management and remote consultation.

AI-Assisted Pathology Diagnosis Software

The company develops assisted pathological diagnosis software that integrates with its scanner platform. This software enables automated image analysis and supports pathologists in diagnostic workflows.

Dian Diagnostics’ AI subsidiary Yice Technology (医策科技) has deployed pathology AI systems including PathoInsight-TCT, PD-L1, and Ki-67 analysis modules across approximately 70 hospitals in Hubei Province, generating over 3 million AI-assisted diagnostic reports. Yice Technology also established China’s first industry standard for cervical cytology pathology image databases.

Molecular Diagnostics

Genedian’s infection disease detection portfolio includes:

• HPV Nucleic Acid Detection Kits (2+5+9 genotyping) with corresponding hybridization instruments
• P16/Ki-67 detection reagent kits for cervical cancer screening
• Immunohistochemistry antibody reagents (354 registered products covering 14 common tissue disease types)
• Monkeypox Virus (MPV) Nucleic Acid Detection Kit (CE certified)
• Tuberculosis screening products using a new tongue swab sample collection method

Technology & Innovation

Genedian is a Hangzhou-based digital pathology subsidiary of Dian Diagnostics, featuring multilayer fusion imaging across up to 15 focal planes and AI-assisted lesion detection for clinical labs.

Genedian’s digital pathology platform incorporates several technical capabilities:

• High-resolution imaging: Constant color fidelity and resolution suitable for histological and cytological sample diagnosis
• Z-stack capture: Multilayer fusion imaging supporting up to 15 focal planes for enhanced depth visualization
• Automation: One-touch scanning operation reducing manual intervention
• Integration: Compatible with laboratory information systems and AI analysis modules

The parent company Dian Diagnostics has accumulated over 1 million pathology samples, with more than 100,000 annotated specimens serving as training data for AI model development across cellular pathology, immunohistochemistry, and tissue pathology applications.

Market Presence

As part of Dian Diagnostics Group, Genedian’s products serve:

• 37 regional laboratories across China
• 22,000+ medical institution clients
• 8,000+ institutions through the “Dian Zhijian” intelligent service platform
• 40,000+ medical professionals

The digital pathology products have been deployed in over 10 hospitals, with the regional inspection digitization platform implemented in 8 facilities as of 2024.

Key Milestones

• 2022: DS600 Digital Pathology Slide Scanner received NMPA Class II registration
• 2024: Parent company obtained 2 Class III and 7 Class II medical device registrations
• 2024: Yice Technology established China’s first pathology AI industry data standard
• 2024: Deployment of digital pathology solutions across Hubei Province hospitals

Frequently Asked Questions

What products does Genedian manufacture?

Genedian produces digital pathology slide scanners (DS12, DS120, DS600), AI-assisted pathology diagnosis software, and molecular diagnostic reagents including HPV detection kits and immunohistochemistry antibodies.

Is Genedian a publicly traded company?

Genedian itself is not publicly traded. It operates as a wholly-owned subsidiary of Dian Diagnostics, which is listed on the Shenzhen Stock Exchange (300244.SZ).

Does Genedian’s equipment have regulatory approval?

Yes. The DS600 digital pathology scanner received NMPA Class II registration in 2022 (Registration No. 浙械注准20222220008). Multiple molecular diagnostic products also hold NMPA registrations.